Carole Faig
Directeur/Membre du Conseil chez HENRY SCHEIN, INC.
Fortune : 198 463 $ au 30/04/2024
Profil
Carole T.
Faig is an Independent Director at Henry Schein, Inc., QuVa Pharma, Inc., and Affinia Therapeutics, Inc. She previously served as an Independent Director at Cue Health, Inc. and as a Partner at Ernst & Young LLP.
Ms. Faig obtained her undergraduate degree from Sam Houston State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
HENRY SCHEIN, INC.
0,00% | 04/03/2024 | 2 604 ( 0,00% ) | 189 623 $ | 30/04/2024 |
CUE HEALTH INC.
0,04% | 31/03/2024 | 60 543 ( 0,04% ) | 8 839 $ | 30/04/2024 |
Postes actifs de Carole Faig
| Sociétés | Poste | Début |
|---|---|---|
| HENRY SCHEIN, INC. | Directeur/Membre du Conseil | 18/12/2023 |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Directeur/Membre du Conseil | 01/09/2021 |
Anciens postes connus de Carole Faig
| Sociétés | Poste | Fin |
|---|---|---|
| CUE HEALTH INC. | Directeur/Membre du Conseil | 24/05/2024 |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Formation de Carole Faig
| Sam Houston State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| HENRY SCHEIN, INC. | Distribution Services |
| CUE HEALTH INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
